- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04973488
Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients
July 20, 2021 updated by: Novacescu Alexandru
Therapeutic plasma exchange (TPE) has been proposed as a rescue therapy in critically ill COVID-19 patients.
The aim of this study is to determine whether combining TPE with convalescent plasma (CVP) transfusion early during the intensive care unit (ICU) stay, improves survival among this heterogeneous population.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This single centre prospective, non-randomised controlled trial will be conducted in an 8 bed COVID-19 ICU and will include patients with severe COVID-19 pneumonia requiring ICU monitoring and therapy.
19 patients will be treated performing TPE followed by CVP transfusion while for 19 patients will receive standard treatment according to hospital protocols.
TPE will be initiated during the first 24 hours after ICU admission, followed immediately by transfusion of CVP.
The primary endpoint is survival at 30 days.
Secondary endpoints include assessing the evolution of biomarkers, such as the partial pressure of arterial oxygen (PaO2) to fractional inspired oxygen (FiO2) ratio (P/F ratio), C reactive protein (CRP), lactate dehydrogenase (LDH) and ferritin at the 7-day follow-up.
Study Type
Interventional
Enrollment (Actual)
38
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Timis
-
Lugoj, Timis, Romania, 305500
- Municipal Hospital "Dr. Teodor Andrei" Lugoj
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- positive reverse transcriptase PCR test for COVID 19
- All patients included were adults (>18 years)
- Acute respiratory failure
Exclusion Criteria:
- pregnant women
- patients with suspected or confirmed pulmonary embolism
- patients with terminal disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment arm
In the treatment arm, Therapeutic plasma exchange will be conducted in the first 24 hours after being admitted into the intensive care unit, after which convalescent plasma from donors that have had COVID-19 will be transfused
|
The intervention is a combination between the procedure of Therapeutic plasma exchange and biological transfusion of convalescent plasma from donors that have have COVID-19
Other Names:
|
NO_INTERVENTION: Control arm
In the control arm, patients will receive standard COVID-19 treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival
Time Frame: 30 day period
|
In percentage
|
30 day period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Partial pressure of arterial oxygen (PaO2) to fractional inspired oxygen (FiO2) ratio (P/F ratio)
Time Frame: 7 day period
|
Evolution of ratio
|
7 day period
|
C reactive protein (CRP)
Time Frame: 7 day period
|
Evolution of value
|
7 day period
|
Lactate dehydrogenase (LDH)
Time Frame: 7 day period
|
Evolution of value
|
7 day period
|
Ferritin
Time Frame: 7 day period
|
Evolution of value
|
7 day period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
- World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Geneva: 2021
- COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health
- Focosi D, Maggi F, Franchini M, et al. Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donorerecipient differences in concentration of neutralizing antibodies. Clin Microbiol Infect. 2021;27(7):987-992
- Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595:283-288
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 25, 2020
Primary Completion (ACTUAL)
January 10, 2021
Study Completion (ACTUAL)
January 10, 2021
Study Registration Dates
First Submitted
July 20, 2021
First Submitted That Met QC Criteria
July 20, 2021
First Posted (ACTUAL)
July 22, 2021
Study Record Updates
Last Update Posted (ACTUAL)
July 22, 2021
Last Update Submitted That Met QC Criteria
July 20, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Infant, Newborn, Diseases
- Lung Injury
- Infant, Premature, Diseases
- COVID-19
- Respiratory Insufficiency
- Respiratory Tract Infections
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
Other Study ID Numbers
- STUDYTPECVP20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
We plan on sharing treatment protocol, demographic data of the study cohort, primary outcomes, secondary outcomes, miscellaneous data, treatment scheme, statystical data
IPD Sharing Time Frame
Data will become available at 6 months after registering the study.
It will be available for 36 months
IPD Sharing Access Criteria
Data will be shared with interested researchers, contact: novacescu_alex@yahoo.com
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Respiratory Distress Syndrome
-
Tanta UniversityRecruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Respiratory Distress Syndrome, PediatricEgypt
-
University Hospital, Clermont-FerrandWithdrawn
-
China-Japan Friendship HospitalNot yet recruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
-
Dr. Behcet Uz Children's HospitalRecruitingAcute Respiratory Distress Syndrome | Acute Respiratory Failure | Pediatric Acute Respiratory Distress Syndrome (PARDS)Turkey
-
Assistance Publique - Hôpitaux de ParisCompletedSevere Acute Respiratory Syndrome Coronavirus 2 | Severe Acute Respiratory Distress SyndromeFrance
-
Intermountain Health Care, Inc.UnknownRespiratory Failure | Acute Respiratory Distress Syndrome (ARDS) | Acute Lung Injury (ALI)United States
-
Aqualung Therapeutics Corp.Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
Unity Health TorontoRecruitingAcute Respiratory Distress Syndrome (ARDS)Canada, Spain, Italy, Brazil
-
Western University, CanadaEnrolling by invitationCOVID-19 Acute Respiratory Distress SyndromeCanada
-
Ain Shams UniversityCompletedCOVID-19 Acute Respiratory Distress SyndromeEgypt
Clinical Trials on Therapeutic plasma exchange
-
Heidelberg UniversityTerminated
-
Larkin Community HospitalUnknown
-
Forsyth Medical CenterNot yet recruiting
-
Alberta Health Services, CalgaryRecruiting
-
Rennes University HospitalCompleted
-
Prisma Health-UpstateCompletedCOVID19 | Cytokine Release SyndromeUnited States
-
Fenwal, Inc.CompletedAutoimmune Diseases | Oncologic Disorders | Renal Disorders | Hematologic DisordersUnited States
-
Alexandria UniversityCompleted
-
Neurological Associates of West Los AngelesEnrolling by invitation
-
Fresenius Medical Care Deutschland GmbHKLIFO GmbHNot yet recruitingAutoimmune DiseasesGermany